Q32 Bio Inc. — Director's Dealing 2018

Mar 27, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27

Reporting Person: TZIANABOS ARTHUR (Director, President & CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	190005	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Options	$0.47	2026-04-22	Common Stock (462135)		Direct
Employee Stock Option	$6.63	2027-12-07	Common Stock (514653)		Direct

Footnotes

F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 1, 2016.

F2: The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018.